MRK

Business Context and Reporting Period

This summary covers the Form 10-Q filed by Schering-Plough Corporation for the quarterly period ended March 31, 2002. The company is a global pharmaceutical and animal health manufacturer. The financial statements are unaudited and prepared in accordance with SEC rules for interim reporting.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 11% ($250 million) year-over-year. Excluding foreign currency effects, sales grew 13%, driven by a 10% volume increase.
• Product Performance:
  • Anti-infective & Anticancer: Sales surged 52% to $797 million, led by the INTRON franchise (up 71%) due to the launch of PEG-INTRON combination therapy.
  • Allergy & Respiratory: Sales rose 9% to $1,014 million. However, CLARITIN sales declined 8% due to patient conversion to the new CLARINEX brand and trade inventory reductions.
  • Cardiovasculars: Sales dropped 29% primarily due to generic competition for K-DUR.
• Profitability: Income before taxes increased 6% to $779 million. Cost of sales as a percentage of sales increased to 22.6% from 20.4%, attributed to higher royalties and manufacturing issues.
• Accounting Changes: The company adopted EITF No. 00-25, reclassifying certain sales incentives as a reduction of Net Sales. Prior year sales were restated by $13 million for comparability.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• CLARITIN Transition: Management expects the elimination of trade inventories for prescription CLARITIN (due to an anticipated switch to OTC status) to negatively impact 2002 pretax profits by approximately $250 million. This is the upper end of the previously projected range.
• Generic Threat: The introduction of generic loratadine or OTC CLARITIN could cause a rapid, sharp, and material decline in sales, potentially similar to the 80% erosion seen with Prozac upon generic entry.
• Capital Expenditures: Expected to exceed $775 million in 2002.
• Dividends: The quarterly dividend was increased to $0.17 per share in April 2002.

Material Risks and Contingencies

• Manufacturing Issues: The company is negotiating a consent decree with the FDA regarding Good Manufacturing Practices (GMP) deficiencies at New Jersey and Puerto Rico facilities. A $500 million provision was recorded in late 2001 for a potential payment under this decree.
• Patent Litigation: Schering-Plough is suing 16 manufacturers regarding generic CLARITIN. While two defendants withdrew challenges to the primary patent, generic entry remains a significant risk if the company does not prevail in remaining suits.
• Government Investigations: The company is under investigation by the DOJ and other agencies regarding marketing practices, "nominally priced" products, and Average Wholesale Price (AWP) reporting. These could result in fines, penalties, or exclusion from government programs.
• Antitrust Actions: Multiple lawsuits allege price-fixing and inflated AWPs. The company is also awaiting a decision on an FTC administrative proceeding regarding patent settlements for K-DUR.

Investor Verification Checklist

• CLARITIN OTC Approval: Monitor FDA decisions on the switch of CLARITIN to OTC status and the timing of generic loratadine market entry.
• FDA Consent Decree: Verify the final terms of the consent decree regarding manufacturing facilities and the impact of the $500 million provision.
• Legal Exposure: Track the outcomes of the DOJ investigations into marketing practices and the various state/federal lawsuits regarding AWP reporting.
• PEG-INTRON Supply: Confirm the resolution of supply constraints for PEG-INTRON and the status of the "Access Assurance" waitlist.
• Trade Inventory Levels: Assess the actual depletion of CLARITIN trade inventories versus management's projections for the remainder of 2002.